Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 6/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900831 | 0.83 | CXCL8 (0.50) | AKR1B1CA2CAMK2ATTRCXCL8 | |
| SCHEMBL11078314 | 0.82 | AKR1B1 (0.67) | AKR1B1CA2CAMK2ATTRPOLB | |
| Hydrochloric Acid SCHEMBL11408340 | 0.81 | CXCL8 (0.49) | AKR1B1CA2CAMK2ATTRCXCL8 | |
| SCHEMBL21617921 | 0.78 | AKR1B1 (0.45) | AKR1B1CA2CAMK2ATTRMAPT | |
| SCHEMBL6137046 | 0.78 | CXCL8 (0.42) | AKR1B1CAMK2ATTRTDP1CXCL8 | |
| SCHEMBL9477716 | 0.78 | AKR1B1 (0.45) | AKR1B1CA2CAMK2ATTRCXCL8 | |
| SCHEMBL30940438 | 0.76 | AKR1B1 (0.58) | AKR1B1CA2CAMK2APOLBKDM4E | |
| SCHEMBL22798814 | 0.76 | AKR1B1 (0.58) | AKR1B1CAMK2ATTRKDM4EMAPT | |
| SCHEMBL8685874 | 0.76 | AKR1B1 (0.58) | AKR1B1CA2CAMK2APOLBKDM4E | |
| SCHEMBL29051963 | 0.75 | AKR1B1 (0.61) | AKR1B1CA2CYP3A4MAPK1CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039187-A1 | GUANIDINOBENZOIC ACID COMPOUND | アステラス製薬株式会社 (JP) | 2013-03-21 | — | — | WO | disclosed |
| EP-1011651-B1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1011651-A1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | Merck & Co., Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-1011651-A4 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO INC (US) | 2000-06-28 | — | — | EP | disclosed |
| US-6020382-A | Method of treating diabetes and related disease states | MERCK & CO., INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-5847008-A | Method of treating diabetes and related disease states | MERCK & CO., INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997027847-A1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| EP-0106565-B1 | LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THEM | MERCK FROSST CANADA INC. (CA) | 1986-09-10 | — | — | EP | disclosed |
| EP-0106565-A1 | Leukotriene antagonists, their production, and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | AKR1B1 1375/4885CA2 801/4885CYP3A4 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.